Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus.
cytokines
drug-resistance
mTOR–mammalian target of rapamycin
neuroendocrine tumors
somatostatin analogs
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
01
2020
accepted:
27
05
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
Somatostatin analogs mantain their major role in the treatment of patients with advanced neuroendocrine tumors (NETs) and have multiple modulatory effects on the immune system. Here, we evaluated the effects of lanreotide treatment on expression of Th1, Th2 cytokine patterns in serum of patients with NETs and in bronchial and pancreatic NET cell lines. Our results showed that lanreotide treatment promoted a Th1 cytotoxic immune-phenotype in patients with NETs originated by intestinal sites. Similar results were obtained also
Identifiants
pubmed: 32766136
doi: 10.3389/fonc.2020.01047
pmc: PMC7379869
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1047Informations de copyright
Copyright © 2020 Sciammarella, Luce, Riccardi, Mocerino, Modica, Berretta, Misso, Cossu, Colao, Vitale, Necas, Fedacko, Galdiero, Correale, Faggiano, Caraglia, Capasso and Grimaldi.
Références
Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22
pubmed: 19143635
Endocrine. 2017 Jun;56(3):603-620
pubmed: 27688013
Expert Opin Drug Saf. 2017 Oct;16(10):1149-1161
pubmed: 28705090
Nucl Med Rev Cent East Eur. 2016;19(2):111-7
pubmed: 27479788
Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88
pubmed: 19845567
Pharmacol Ther. 2015 Aug;152:98-110
pubmed: 25956467
Front Neuroendocrinol. 1999 Jul;20(3):157-98
pubmed: 10433861
Virchows Arch. 2007 Aug;451 Suppl 1:S71-80
pubmed: 17684765
Oncologist. 2016 Jul;21(7):875-86
pubmed: 27053503
J Clin Endocrinol Metab. 2013 Oct;98(10):E1567-74
pubmed: 23884781
Int J Mol Sci. 2019 Aug 13;20(16):
pubmed: 31412614
World J Gastroenterol. 2013 Dec 21;19(47):9012-9
pubmed: 24379626
Cancer Lett. 2012 Jun 1;319(1):1-7
pubmed: 22261336
J Neuroimmunol. 2007 Jan;182(1-2):153-9
pubmed: 17113654
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Cell. 2012 Apr 13;149(2):274-93
pubmed: 22500797
Aliment Pharmacol Ther. 1999 May;13(5):583-94
pubmed: 10233181
Br J Cancer. 2005 Apr 25;92(8):1506-16
pubmed: 15846300
Lancet Oncol. 2017 Dec;18(12):1652-1664
pubmed: 29074099
Gut. 1996 Mar;38(3):430-8
pubmed: 8675099
Cancer Res. 2003 Oct 15;63(20):6784-90
pubmed: 14583474
Int J Mol Sci. 2018 Mar 06;19(3):
pubmed: 29509701
Endocr Relat Cancer. 2013 Jun 24;20(4):463-75
pubmed: 23653462
J Clin Oncol. 2016 Nov 10;34(32):3906-3913
pubmed: 27621394
Future Oncol. 2012 Oct;8(10):1273-99
pubmed: 23130928
Minerva Endocrinol. 2010 Mar;35(1):17-25
pubmed: 20386524
FASEB J. 1993 Aug;7(11):1055-60
pubmed: 8370476
JAMA Oncol. 2016 Feb;2(2):242-6
pubmed: 26719971
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Endocr Relat Cancer. 2014 May 06;21(3):R153-63
pubmed: 24322304
Int Immunol. 2016 Aug;28(8):393-9
pubmed: 27401477
J Cancer Res Clin Oncol. 2017 Jul;143(7):1209-1224
pubmed: 28405826
J Immunother. 1997 May;20(3):165-77
pubmed: 9181454
Expert Opin Investig Drugs. 2009 Sep;18(9):1297-316
pubmed: 19678799
Visc Med. 2017 Oct;33(5):324-330
pubmed: 29177160
N Engl J Med. 1996 Jan 25;334(4):246-54
pubmed: 8532003
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
J Clin Endocrinol Metab. 2000 Mar;85(3):983-8
pubmed: 10720027
Int J Mol Sci. 2019 Jun 22;20(12):
pubmed: 31234481
J Neuroimmunol. 2004 Apr;149(1-2):210-6
pubmed: 15020082